Equities

CanBas Co Ltd

4575:TYO

CanBas Co Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (JPY)1,274.00
  • Today's Change-5.00 / -0.39%
  • Shares traded3.96m
  • 1 Year change+38.48%
  • Beta-0.7756
Data delayed at least 20 minutes, as of Sep 20 2024 07:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of JPY
(except for per share items)
Fiscal data as of Jun 30 2024202420232022
ASSETS
Cash And Short Term Investments1,8881,618738
Total Receivables, Net2756.706.53
Total Inventory0.730.771.07
Prepaid expenses14538113
Other current assets, total0.00610.69
Total current assets2,3082,068759
Property, plant & equipment, net------
Goodwill, net------
Intangibles, net------
Long term investments------
Note receivable - long term------
Other long term assets951832
Total assets2,4332,086791
LIABILITIES
Accounts payable------
Accrued expenses----0.94
Notes payable/short-term debt--00
Current portion long-term debt/capital leases--0--
Other current liabilities, total92154172
Total current liabilities92154173
Total long term debt--0367
Total debt--0367
Deferred income tax------
Minority interest------
Other liabilities, total--0.000.00
Total liabilities92154540
SHAREHOLDERS EQUITY
Common stock7,5866,7785,286
Additional paid-in capital7,5726,7645,273
Retained earnings (accumulated deficit)(12817)(11609)(10309)
Treasury stock - common(0.4)(0.39)(0.3)
Unrealized gain (loss)------
Other equity, total0--0.00
Total equity2,3411,932251
Total liabilities & shareholders' equity2,4332,086791
Total common shares outstanding181612
Treasury shares - common primary issue0.000.000.00
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.